Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma

被引:57
作者
Garey, KW
Rubinstein, I
Gotfried, MH
Khan, IJ
Varma, S
Danziger, LH
机构
[1] Univ Illinois, Dept Med, Sect Resp & Crit Care Med, Chicago, IL 60612 USA
[2] Good Samaritan Reg Med Ctr, Phoenix, AZ USA
关键词
anti-inflammatory; clarithromycin; macrolides; prednisone-dependent asthma;
D O I
10.1378/chest.118.6.1826
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Prolonged use of prednisone is associated with serious side effects, such as osteoporosis, particularly among elderly individuals. Macrolide antibiotics exhibit anti-inflammatory effects that are distinct from their antimicrobial properties. Thus, the purpose of this case report is to describe the effects of prolonged treatment with clarithromycin, 500 mg bid, in reducing prednisone requirements in three elderly patients with prednisone-dependent asthma, Three patients (one woman and two men) aged 63 to 69 years, who had been treated with 5 to 10 mg prednisone daily for at least the last 12 months, were given clarithromycin, 500 mg bid. They were followed regularly for changes in daily prednisone dose, spirometry, quality of life, and adverse events. The prednisone dose was tapered in a stepwise fashion at each clinic visit. Within 3 to 6 months of initiation of treatment with clarithromycin, and throughout the 12-month follow-up, two of three patients discontinued prednisone therapy, while the third patient displayed increased spirometry readings and noted an increasingly better quality of life, Pulmonary function tests were stable or improved over this time period, with no reported adverse events, including increased rate of infections. One patient relapsed upon discontinuation of clarithromycin therapy but has since responded to re-initiation of treatment. Long-term oral clarithromycin may have a role in reducing prednisone requirements in elderly patients with prednisone-dependent asthma.
引用
收藏
页码:1826 / 1827
页数:2
相关论文
共 13 条
[1]   Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils [J].
Anderson, R ;
Theron, AJ ;
Feldman, C .
INFLAMMATION, 1996, 20 (06) :693-705
[2]  
BLACK PN, 1996, EUR RESPIR REV, V6, P240
[3]  
DUNLAP NE, 1990, SOUTHERN MED J, V83, P428
[4]   Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro [J].
Feldman, C ;
Anderson, R ;
Theron, AJ ;
Ramafi, G ;
Cole, PJ ;
Wilson, R .
INFLAMMATION, 1997, 21 (06) :655-665
[5]   Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy [J].
Fost, DA ;
Leung, DYM ;
Martin, RJ ;
Brown, EE ;
Szefler, SJ ;
Spahn, JD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) :1031-1035
[6]   USE OF MACROLIDE ANTIBIOTIC SUBSTANCES IN TREATMENT OF ASTHMA [J].
ITKIN, IH ;
MENZEL, ML .
JOURNAL OF ALLERGY, 1970, 45 (03) :146-&
[7]   THE MACROLIDE ANTIBACTERIAL ROXITHROMYCIN REDUCES BRONCHIAL HYPERRESPONSIVENESS AND SUPEROXIDE ANION PRODUCTION BY POLYMORPHONUCLEAR LEUKOCYTES IN PATIENTS WITH ASTHMA [J].
KAMOI, H ;
KURIHARA, N ;
FUJIWARA, H ;
HIRATA, K ;
TAKEDA, T .
JOURNAL OF ASTHMA, 1995, 32 (03) :191-197
[8]   ANTIASTHMATIC ACTIVITY OF A MACROLIDE ANTIBIOTIC, ROXITHROMYCIN - ANALYSIS OF POSSIBLE MECHANISMS IN-VITRO AND IN-VIVO [J].
KONNO, S ;
ASANO, K ;
KUROKAWA, M ;
IKEDA, K ;
OKAMOTO, K ;
ADACHI, M .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1994, 105 (03) :308-316
[9]  
Labro M. T., 1998, Journal of Antimicrobial Chemotherapy, V41, P37, DOI 10.1093/jac/41.suppl_2.37
[10]   ERYTHROMYCIN REDUCES THE SEVERITY OF BRONCHIAL HYPERRESPONSIVENESS IN ASTHMA [J].
MIYATAKE, H ;
TAKI, F ;
TANIGUCHI, H ;
SUZUKI, R ;
TAKAGI, K ;
SATAKE, T .
CHEST, 1991, 99 (03) :670-673